ing the interference and cementing Editas' IP position in eukaryotic =ells. While scenarios remain where other parties can collect some =oundational CRISPR IP, Editas has derisked concerns around its freedom =o operate. The USPTO issued final judgment in favor of the Broad Institute/Editas =n the interfer